Ebos Group Limited · NZX:EBO
Ebos — Investor Presentation (April 2025)
38 slides from Ebos's investor presentation, Apr 10, 2025
Slide 1: Investor Presentation: Raising and Equity Acquisitions
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only 10 April 2025 RAISING INVESTOR PRESENTATION AND EQUITY ACQUISITIONS
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER The following notice and disclaimer applies to this investor presentation (Presentation) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting th
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER NOT INVESTMENT ADVICE This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by EBOS or its advisers to acquire New Shares and does not and will not form any part of any contract for the
Slide 4: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER FINANCIAL DATA (CONT.) All currency amounts are in Australian dollars unless stated otherwise. NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES This Presentation includes certain pro forma financial information to reflect the impact of the Placement and the Retail
Slide 5: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER DISCLAIMER The information contained in this Presentation has been prepared in good faith by EBOS. No representation or warranty, expressed or implied, is made by any person NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES (including by any of the Specified Person
Slide 6: Important Notice and Disclaimer (cont.)
IMPORTANT NOTICE AND DISCLAIMER DISCLAIMER (CONT.) The Lead Manager and Underwriter is acting for and providing services to EBOS in relation to the Placement and will not be acting for or providing services to EBOS' NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES shareholders or creditors. The
Slide 7: Contents
CONTENTS NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 1 Executive summary 8 For personal use only 2 Overview of SVS 11 3 Transmedic update 15 4 Equity raising details 20 5 Appendices 24 • Key risks • International offer restrictions 7
Slide 8: Executive Summary
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 8 For personal use only SUMMARY EXECUTIVE
Slide 9: Executive Summary
EXECUTIVE SUMMARY EBOS is raising up to A$250m (NZ$272m) via a placement and retail offer to fund two bolt-on acquisitions NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only • Consistent with EBOS’ strategy of investing for growth, the Group has completed two acquisitions (to
Slide 10: Executive Summary
EXECUTIVE SUMMARY • Transmedic is a leading independent medical device distributor in Southeast Asia with a presence across Singapore, NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Acquisition of Indonesia, Malaysia, Philippines, Thailand, Hong Kong and Vietnam For personal use only remaining
Slide 11: Overview of SVS
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only SVS OVERVIEW OF
Slide 12: SVS Investment Highlights
SVS INVESTMENT HIGHLIGHTS NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES SVS is a leading supplier in the New Zealand vet wholesale sector For personal use only ✓ ✓ Vet wholesale distribution is mature and stable and is supported by category trends such as humanisation of pets and premiumisati
Slide 13: Overview of SVS
OVERVIEW OF SVS SVS is a leading supplier of veterinary and other animal care products in New Zealand NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only Overview Revenue (NZ$ million)2 3 255 266 ~280 • Founded in 1987, SVS is a leading supplier of pet medicines and 234 other
Slide 14: EBOS' Animal Care Business
EBOS’ ANIMAL CARE BUSINESS SVS is a natural extension of EBOS’ established vet wholesale business into the New Zealand market NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only Pet Brands Vet Wholesale Pet Retail A leading pet brands marketer and manufacturer for specialty pr
Slide 15: Transmedic Update
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only UPDATE TRANSMEDIC
Slide 16: Southeast Asia Is an Attractive Healthcare Market
SOUTHEAST ASIA IS AN ATTRACTIVE HEALTHCARE MARKET Highly attractive market with expected growth due to a large, growing and ageing population with increasing wealth and access to healthcare NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only Southeast Asia medical device marke
Slide 17: Transmedic Overview
TRANSMEDIC OVERVIEW Transmedic is a leading independent medical device distributor in Southeast Asia NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Overview Presence in Southeast Asia1 For personal use only • Transmedic was established in 1980 and is headquartered in + Hong Kong Singapore • Di
Slide 18: Transmedic Has Performed Strongly Under EBOS' Ownership
TRANSMEDIC HAS PERFORMED STRONGLY UNDER EBOS’ OWNERSHIP Transmedic has grown significantly since EBOS’ acquisition, providing further confidence in the Southeast Asian expansion strategy NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only Transmedic revenue Transmedic under EB
Slide 19: EBOS' Medical Technology Business
EBOS’ MEDICAL TECHNOLOGY BUSINESS EBOS’ Medical Technology division distributes and manufactures medical technologies across Asia Pacific and the US with significant market presence in several growing therapeutic areas NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only ANZ So
Slide 20: Equity Raising Details
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only EQUITY DETAILS RAISING
Slide 21: Details of the Offer
DETAILS OF THE OFFER NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES • Fully underwritten placement to eligible investors to raise approximately A$200 million (NZ$217 million1,2) (Placement) For personal use only • Approximately 5.9 million new shares to be issued under the Placement, represent
Slide 22: Use of Proceeds
USE OF PROCEEDS • EBOS will raise approximately A$200 million (NZ$217 million) via a fully underwritten placement to eligible investors NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES • Funds raised in excess of the amounts paid for the Acquisitions will provide further balance sheet capacity,
Slide 23: Equity Raising Timetable
EQUITY RAISING TIMETABLE Description Date (NZST)1 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Record date for Retail Offer 7pm, Wednesday, 9 April 2025 For personal use only Trading halt lodged on NZX and ASX Thursday, 10 April 2025 Announcement of the Placement and Retail Offer, Placement
Slide 24: Appendix – Key Risks
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only KEY RISKS APPENDIX –
Slide 25: Key Risks
KEY RISKS Risk Description KEY RISKS ASSOCIATED WITH EBOS NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Product liability EBOS may, from time to time, experience product defects or other claims relating to its products or services. Defects in products that EBOS markets, For personal use only
Slide 26: Key Risks
KEY RISKS Risk Description KEY RISKS ASSOCIATED WITH EBOS NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Regulatory risk and EBOS operates in a number of highly regulated industry segments, including in relation to the distribution and supply of pharmaceutical, medical and For personal use onl
Slide 27: Key Risks
KEY RISKS Risk Description KEY RISKS ASSOCIATED WITH EBOS NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Employment risk EBOS may be adversely impacted by industrial relations issues in connection with its employees or the employees of its customers, contractors and For personal use only suppl
Slide 28: Key Risks
KEY RISKS Risk Description KEY RISKS ASSOCIATED WITH EBOS NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Future dividends No assurance can be given in relation to the payment of future dividends. Future determinations as to the payment of dividends by EBOS will be at the For personal use only
Slide 29: Key Risks
KEY RISKS Risk Description KEY RISKS ASSOCIATED WITH EBOS NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Changes to Changes to accounting standards that apply to EBOS could materially adversely affect the financial position and performance reported in EBOS’ For personal use only accounting fin
Slide 30: Key Risks
KEY RISKS Risk Description RISKS ASSOCIATED WITH THE OFFER NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Underwriting Risk • any event specified in the timetable is delayed for more than 1 business day without the approval of UBS (not to be unreasonably withheld or For personal use only delay
Slide 31: Key Risks
KEY RISKS Risk Description RISKS ASSOCIATED WITH THE OFFER NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Underwriting Risk • a director, officer, or member of the executive management team of EBOS is: For personal use only (cont.) o charged with an indictable offence, an offence involving dis
Slide 32: Key Risks
KEY RISKS Risk Description RISKS ASSOCIATED WITH THE OFFER NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Market risk In addition to EBOS specific factors, the price of EBOS securities on the ASX and NZX may rise or fall due to numerous factors including: For personal use only • New Zealand, A
Slide 33: Appendix – International Offer Restrictions
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only OFFER APPENDIX – RESTRICTIONS INTERNATIONAL
Slide 34: International Offer Restrictions
INTERNATIONAL OFFER RESTRICTIONS This document does not constitute an offer of new ordinary shares (New Shares) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any c
Slide 35: International Offer Restrictions
INTERNATIONAL OFFER RESTRICTIONS CANADA (BRITISH COLUMBIA, ONTARIO AND QUEBEC PROVINCES) (CONT.) Statutory rights of action for damages and rescission. Securities legislation in certain Provinces may provide a purchaser with remedies for rescission or damages if an offering NOT FOR DISTRIBUTION OR R
Slide 36: International Offer Restrictions
INTERNATIONAL OFFER RESTRICTIONS LUXEMBOURG This document has not been, and will not be, registered with or approved by any securities regulator in Luxembourg or elsewhere in the European Union. Accordingly, this NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES document may not be made available
Slide 37: International Offer Restrictions
INTERNATIONAL OFFER RESTRICTIONS UNITED ARAB EMIRATES This document does not constitute a public offer of securities in the United Arab Emirates and the New Shares may not be offered or sold, directly or indirectly, to the public NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES in the UAE. Neith
Slide 38: www.ebosgroup.com
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only www.ebosgroup.com